Cancer is the biggest therapeutic area for licensing deals. But there are almost 3,000 drugs in Phase 1 through Phase 3, so competition for licensing deals and for market position is huge. Checkpoint inhibitors have benefits in most tumors and have made combination trials an industry standard. But everything in immuno-oncology has become so crowded that differentiation is key. So what are the areas everyone is seeking?
Life science founders are technical experts in their fields, but frequently fail to understand the needs of the stakeholders who will determine their path to market. This gap sends investors running, and all but ensures immediate or eventual company failure.
Once aware of this gap in knowledge, many are:
Interest in investing in healthcare services and technology companies is at unprecedented levels. Supported by enormous reserves of capital, large companies, private equity firms, and family offices are buying medical groups and healthcare companies across the healthcare space. With this level of interest comes generally higher valuations, but also more pitfalls for sellers.
Just 7 years since Novartis paid UPenn $20M to access Carl June’s anti-CD19 CAR-T technology, the field of adoptive cell therapy (ACT) in cancer has expanded dramatically, both in investment activity and technology proliferation. At present, it is estimated that there are at least 150 pre-commercial ACT-focused companies in the US and EU alone, many of which are less than 5 years old. While some of these newcos are pursuing fast-follower strategies, many are developing novel technology platforms, each with a unique value proposition that has proven sufficient to incentivize investors.
Central nervous system disorders include diseases with millions of patients (such as schizophrenia, Alzheimer’s and depression), and they also include rare diseases, such as SMA (spinal muscular atrophy), Friedreich Ataxia, and ALS (amyotrophic lateral sclerosis). Many CNS diseases have no treatments or unsatisfactory treatments, and many of them place a tremendous burden on families and society because they result in a “loss of self.”
In this white paper, LMK evaluates the following:
This white paper is based on the panel discussion, where four life science founders provided guidance on how executive teams can partner business and science together to overcome the stumbling blocks along the way and achieve results...
Successful BioPharma partnerships don't happen by accident. And negotiating an out-licensing deal can be a daunting task – especially if the company is progressing the clinical portfolio. This white paper provides you perspectives on the major steps required for a successful transaction.
In order to thrive, biotechnology firms must successfully license their discoveries or partner with large pharmaceutical firms to develop their product. The right time to seek a partnering or licensing agreement and who to seek it with can be a daunting task, but breaking it down into the major elements that need to be considered will help you to develop an actionable plan.
In this white paper, Carlos N. Velez, founder of Lacerta Bio, will discuss how companies define their business development goals, develop a tailored process and execute it. He’ll discuss the challenges presented by organizational structure and the importance of goal setting, flexibility and realistic strategy design. He’ll explain...